A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats.
BACKGROUND
Treatment of ischemic heart disease (IHD) remains a worldwide problem. Gene therapy, and recently, cell transplantation, have made desirable progress. A combination of appropriate stem cells and angiogenic genes appears promising in treating IHD.


OBJECTIVE
To study the results of angiogenesis and myogenesis induced by transplantation of the adenovirus carrying human vascular endothelial growth factor 165 (Ad-hVEGF(165))-transfected mesenchymal stem cells (MSCs) in IHD compared with direct MSC transplantation or Ad-hVEGF165 delivery.


METHODS
Cultured MSCs were transfected by Ad-hVEGF(165), and secreted VEGF was measured by ELISA in vitro. Ad-hVEGF(165)-transfected MSCs (MSC/VEGF group), MSCs (MSC group), Ad-hVEGF(165) (VEGF group) or a serum-free medium (control group) was injected into syngeneic Wistar rats immediately after left coronary artery occlusion. All cells were marked with CM-DiI (Molecular Probes, USA) before transplantation. One week after treatment, messenger RNA expression of hVEGF(165) in the MSC/VEGF group was found to be significantly higher than in other groups by reverse transcriptase-polymerase chain reaction analysis. One month after cell transplantation, left ventricular (LV) ejection fraction, capillary density of the infarcted region, infarct size and hemodynamic parameters (including LV end-diastolic pressure, LV+dP/dt and LV-dP/dt) were measured and immunohistochemical analysis was performed.


RESULTS
A high level of VEGF was expressed by Ad-hVEGF(165)-transfected MSCs. LV ejection fraction, mean capillary density of the infarcted region and hemodynamic parameters were significantly improved in the MSC/VEGF group compared with the MSC group, the VEGF group and the control group (P<0.001 for all). Partly transplanted MSCs showed the cardiomyocyte phenotype, expressed desmin and cardiac troponin T, and resulted in angiogenesis in the ischemic myocardium. However, a few transplanted MSCs incorporated into the vascular structure and most of the new vascular components were host-derived.


CONCLUSIONS
The combined strategy of MSC transplantation and VEGF gene therapy can produce effective myogenesis and host-derived angiogenesis, resulting in the prevention of progressive heart dysfunction after myocardial infarction.
Gao
Feng
F
Xijing Hospital, Fourth Military Medical University, ShaanXi, China.
He
Tao
T
Wang
HongBing
H
Yu
ShiQiang
S
Yi
DingHua
D
Liu
WeiYong
W
Cai
ZhenJie
Z
D000818:Animals; D003893:Desmin; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D009203:Myocardial Infarction / Q000150:complications; D017202:Myocardial Ischemia / Q000235:genetics / Q000628:therapy*; D009206:Myocardium; D032383:Myocytes, Cardiac; D018919:Neovascularization, Physiologic; D010641:Phenotype; D012333:RNA, Messenger; D051381:Rats; D017208:Rats, Wistar; D013318:Stroke Volume; D014162:Transfection; D020107:Troponin T; D042442:Vascular Endothelial Growth Factors
D003893:Desmin; D012333:RNA, Messenger; D020107:Troponin T; D042442:Vascular Endothelial Growth Factors